论文部分内容阅读
利福定(异丁基哌嗪力复霉素,R-76-1)系利福霉素类衍生物,自1976年研制成功并投放市场以来,多年的临床实践表明,利福定对结核杆菌及麻风杆菌具有与利福平相似的抗菌作用,吸收好,毒副反应小,疗效高,抗菌能力较利福平强,治疗费用低,因而受到广大患者的青睐。目前利福定已在我国的抗痨药物方面占有重要地位。利福定在生产过程中由于结晶的条件不同,出现Ⅰ、Ⅱ、Ⅲ、Ⅳ四种晶型,业已证明不同晶型在人工胃肠液中溶解度亦不同,Ⅰ、Ⅴ型溶解度好,Ⅱ、Ⅲ型较差,血浓和尿药排泄量也有相似的规
Rifadin (isobutylpiperazine rifamycins, R-76-1) is a derivative of rifamycins, since 1976 developed and put on the market, many years of clinical practice shows that Rifadin TB Bacillus and leprosy with rifampicin similar antibacterial effect, good absorption, small side effects, high efficacy, anti-bacterial ability than rifampicin, low cost, which by the majority of patients of all ages. Currently, Rifadin occupies an important position in anti-tuberculosis drugs in our country. There are four crystal forms of Ⅰ, Ⅱ, Ⅲ and Ⅳ due to the different crystallization conditions in the production process of rifamycin. The solubility of different crystal forms in artificial gastrointestinal liquid has also been proved to be different. The solubility of type Ⅰ and Ⅴ is good. Type Ⅲ is poor, blood concentration and urinary excretion also have similar rules